Arvinas and Pfizer's Veppanu, the First PROTAC Breast Cancer Treatment, Receives Early FDA Approval
The Birth of the First PROTAC Treatment and its Early FDA Approval
Veppanu (vepdegestrant), co-developed by Arvinas and Pfizer, received FDA approval on May 1st, ahead of the PDUFA target date of June 5th, 2026. This decision marks a historic milestone as it is the first commercial approval of a treatment utilizing PROTAC (PROteolysis TArgeting Chimera) technology, a targeted protein degradation (TPD) platform. Veppanu demonstrates an innovative mechanism of action by utilizing the body's natural waste disposal system to degrade estrogen receptor (ER) proteins, which are difficult to eliminate with conventional drugs, thereby inhibiting the proliferation of cancer cells. The rapid approval without an advisory committee (AdComm) meeting demonstrates the sufficient evidence of the efficacy of this new technology in the breast cancer market, which has a high unmet medical need.
A Precision Targeted Treatment Option for Breast Cancer Patients with ESR1 Mutations
This approval is intended for adult patients with estrogen receptor-positive (ER+), HER2-negative breast cancer who have progressed after endocrine therapy, specifically those with ESR1 gene mutations. ESR1 mutations are known to cause strong resistance to existing endocrine therapies, which is a major cause of decreased survival rates in patients. Veppanu selectively degrades these resistant mutant proteins, inhibiting tumor growth and providing an optimal personalized alternative for patients who have failed standard treatments. The simultaneous approval of the companion diagnostic device, Guardant360 CDx, will maximize the accuracy of patient selection, enabling more precise biomarker-based treatment in clinical practice.
Commercial Success Amidst Fierce Competition and Re-evaluation of Partnership
Despite its innovative technology, Veppanu faces concerns from investors and skepticism from the market regarding its commercial success. Menarini's Orserdu, the first oral SERD treatment, has already established a presence in the market, and strong competitors such as AstraZeneca's camizestrant and Roche's giredestrant are completing Phase 3 trials. In response, Pfizer and Arvinas agreed in September 2025 to re-evaluate the existing partnership terms and seek a third commercialization partner to efficiently operate a global marketing network. By establishing a commercial partnership, they can share the burden of marketing costs and aim for rapid market penetration.
Driving Re-evaluation of the Value of Innovative Pipelines in Bio Companies
The approval of Veppanu has not only increased the value of Arvinas' other PROTAC candidates but also enhanced the credibility of TPD technology-based pipelines in the industry. Arvinas is currently expanding its therapeutic platform to various difficult-to-treat diseases, including Parkinson's disease and spinal muscular atrophy (SBMA), in addition to oncology. The news of this approval immediately caused Arvinas' stock price to rise by 7%, reflecting market expectations, and has provided strong evidence for the commercial viability of protein degradation technology. In the future, pharmaceutical companies will expand their investment in the development of treatments that utilize the body's waste disposal mechanisms, rather than simply inhibiting them, and this will be a long-term momentum that will change the paradigm of drug development.
Veppanu's approval signifies the entry of the first PROTAC drug into the commercial stage in the ESR1-mutated metastatic breast cancer market, which is valued at $1.3 billion in 2023 across the 7 major countries (7MM) and is expected to grow at a CAGR of 9.6% until 2036. From an investor's perspective, the key factor determining Arvinas' long-term valuation will be demonstrating clinical differentiation from existing oral SERD treatments such as Menarini's Orserdu and late-stage pipeline drugs such as AstraZeneca's camizestrant. From the perspective of researchers and industry professionals, this approval will serve as the first case of overcoming the safety hurdles of targeted protein degradation (TPD) platforms, which will promote the development of pipelines in other areas such as neurodegenerative diseases. In the short term, the details and upfront payment amount of the third-party global commercialization license agreement that Pfizer and Arvinas are pursuing will determine the potential for further increases in corporate value.
Source: BioPharma Dive (rss)